Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
---|---|---|---|---|---|---|---|---|
BIOTECHNOLOGY VALUE FUND L P | 9.99% | $15.6M | 4.83M | BVF PARTNERS L P/IL | Dec 31, 2024 | |||
RA CAPITAL MANAGEMENT, L.P. | 9.9% | $14.8M | 4.56M | RA Capital Management, L.P. | Dec 31, 2024 | |||
GOLDMAN SACHS GROUP INC | 9.6% | $14.3M | 4.42M | THE GOLDMAN SACHS GROUP, INC. | Dec 31, 2024 | |||
BlackRock, Inc. | 7.8% | $11.7M | 3.62M | BlackRock, Inc. | Mar 31, 2025 | |||
Venrock Healthcare Capital Partners III, L.P. | 6.4% | $9.54M | 2.95M | Venrock Healthcare Capital Partners III, L.P. | Dec 31, 2024 | |||
JANUS HENDERSON GROUP PLC | 4.9% | $7.28M | 2.25M | JANUS HENDERSON GROUP PLC | Dec 31, 2024 | |||
Deep Track Capital, LP | 1.32% | $1.97M | 610K | Deep Track Capital, LP | Dec 31, 2024 |
Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
---|---|---|---|---|---|
2025 Q1 | 795K | $2.57M | -$56.7K | $3.23 | 6 |
2024 Q4 | 46.8M | $261M | -$76.3M | $5.57 | 139 |
2024 Q3 | 57.4M | $621M | -$40.1M | $10.81 | 134 |
2024 Q2 | 57.3M | $1.2B | +$3.36M | $20.99 | 140 |
2024 Q1 | 56.2M | $1.79B | +$449M | $31.86 | 147 |
2023 Q4 | 40.9M | $828M | +$22.8M | $20.26 | 110 |
2023 Q3 | 41.9M | $533M | +$919K | $12.73 | 109 |
2023 Q2 | 41.2M | $745M | +$197M | $18.07 | 99 |
2023 Q1 | 30.4M | $522M | +$35M | $17.19 | 92 |
2022 Q4 | 28M | $622M | +$47.6M | $22.21 | 95 |
2022 Q3 | 22.8M | $183M | -$11.6M | $8.04 | 80 |
2022 Q2 | 24.7M | $172M | +$978K | $6.98 | 83 |
2022 Q1 | 25.3M | $382M | +$19.4M | $15.12 | 70 |
2021 Q4 | 23.4M | $513M | +$75.3M | $21.94 | 72 |
2021 Q3 | 18.8M | $505M | +$68.6M | $26.97 | 61 |
2021 Q2 | 16.2M | $389M | -$3.19M | $24.08 | 52 |
2021 Q1 | 15.4M | $665M | +$47.8M | $43.38 | 64 |
2020 Q4 | 13M | $536M | +$512M | $41.45 | 50 |